The effect of the <i>MBL2</i> gene rs1800450 variant on COVID-19 development in Turkish patients
Creators: name: Capraz, Mustafa
name: Tekcan, Akin
name: Cihangiroglu, Mustafa
name: Nursal, Ayse Feyda
name: Capraz, Aylin
name: Menekse, Elif
name: Demir, Hatice Dortok
name: Kuruca, Nilufer
name: Yigit, Serbulent
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Molecular Biology
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Mental Health
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Virology

description: The coronavirus disease 2019 (COVID-19) is a recent pandemic occurring worldwide due to the <i>severe acute respiratory syndrome coronavirus 2</i> (SARS-CoV-2) virus, spreading mainly through large respiratory droplets or maybe through other transmission routes. The human genome has the most varied immune response genes correlated with infectious diseases. Genetic variants of mannose-binding lectin 2 (<i>MBL2</i>), an immunomodulatory gene, were associated with the risk, severity, and frequency of viral infections. In the present study, we hypothesized that the <i>MBL2</i> gene rs1800450 variant could be associated with the development of COVID-19 disease in a Turkish population. Ninety-eight COVID-19 patients and 98 healthy, ethnically matched controls were studied. We isolated genomic DNA from whole blood and analyzed the <i>MBL2</i> rs1800450 using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Associations were analyzed with the SPSS 20 statistical software. We found that <i>MBL2</i> rs1800450 genotype distribution was significantly different between patients and controls. The patients had a higher <i>MBL2</i> rs1800450 AA genotype than the controls had (4.94% in patients vs. 3.12% in controls, <i>p</i> = 0.006). The subjects carrying AA genotype had a 10.83-fold increased risk for COVID-19 disease (OR = 10.83, � CI = 1.359–86.349). We could not detect any significant difference between the COVID-19 patients and healthy controls in allele frequencies. Our findings demonstrated that the <i>MBL2</i> rs1800450 BB genotype might increase the susceptibility to COVID-19 disease in the Turkish population. We suggest further studies with a larger sample size and other ethnic populations. Complement activation is involved in the pathogenesis of cardiovascular diseases through pleiotropic effects on inflammatory processes, endothelial and hematopoetic cell function, and hemostasis.MBL is a serum protein dependent on calcium that is effective in the innate immune response and binds to carbohydrates on the surface of several pathogens, activating the complement system or serving directly as an opsonin.It was found that COVID-19 patients had a higher <i>MBL2</i> gene rs1800450 AA genotype than the controls. Complement activation is involved in the pathogenesis of cardiovascular diseases through pleiotropic effects on inflammatory processes, endothelial and hematopoetic cell function, and hemostasis. MBL is a serum protein dependent on calcium that is effective in the innate immune response and binds to carbohydrates on the surface of several pathogens, activating the complement system or serving directly as an opsonin. It was found that COVID-19 patients had a higher <i>MBL2</i> gene rs1800450 AA genotype than the controls.